8:00 am
Virtual Coffee & Online Registration
8:45 am Chair’s Opening Remarks
9:00 am An In-Depth Overview of Current Research Strategies for Glioblastoma & Barriers to Progress
Synopsis
- Overview of changes in the classification and definition of glioblastoma
- Summary of the major therapeutic strategies currently under
development - Discuss barriers to progress and strategies to address these
9:30 am I’m Still Here – A Long-Term Survivor’s Perspective
Synopsis
- Explore a patient’s GBM story and drug treatments
- Learn how to diagnose GBM patients and what’s involved
- Deep dive into OurBrainBank – a patient-driven movement to turn
glioblastoma from terminal to treatable
IMMUNO-ONCOLOGY & THERAPY
10:00 am Optimize the Role of Immunotherapy for Treatment of Glioblastoma
Synopsis
- Outline the historical and current understanding of the mechanisms of
immune responses against glioblastoma - Discuss the common challenges of designing and evaluating clinical
trials of immunotherapy for glioblastoma - Elucidate the considerations of timing, sequence, and tumor/patient
heterogeneity in developing combination immunotherapy/vaccine trials
for glioblastoma
10:30 am
Morning Break & Virtual Speed Networking
VACCINES
11:00 am An Exclusive Update on Neoantigen Vaccination for Glioblastoma
Synopsis
- Describe rationale for targeting neoantigens for anti-tumor vaccination
- Summarize therapeutic development of neoantigen vaccination for
oncology to date - Overview results of neoantigen vaccination application for glioblastoma
- Enhance next steps to optimize neoantigen vaccination for glioblastoma
11:30 am Examine the Absolute Utilization of Vaccine Immunotherapy to Treat Glioblastoma
Synopsis
- Explore immunotherapy with vaccines that can be used to treat GBM
- Evaluate personalized vaccines and off-the-shelf vaccines
- Discuss use of vaccines in combination treatments for GBM
12:00 pm PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma
Synopsis
- A year on from the inaugural GBM Drug Development meeting: What have we learnt?
- How can drug developers cut to the real barriers, and debate what is truly required to break through to
successful treatments for GBM? - The impact of COVID-19 and its repercussions on existing clinical trials
12:45 pm
Virtual Coffee & Online Registration
1:45 pm Exhausted T-cells for GBM Immunotherapy: An Exclusive Look at Fresh GBM Clinical Trial Results
Synopsis
- Discuss concept of exhaustion in T-cells
- Examine GBM specific immunosuppression
- Evaluate results from recent Glioblastoma patient clinical trials
2:15 pm Empower the Immune System to Treat Glioblastoma: DNA as Medicine
Synopsis
- Explore DNA medicines that have the potential to create robust,
antigen-specific T cell responses - Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in
GBM showing early efficacy, and immunogenicity - Discuss Inovio’s DNA medicine, its technology, and other promising
approaches to GBM therapy will be discussed
2:45 pm Updated Clinical Results in Recurrent Glioblastoma for VBI1901 – A Therapeutic Vaccine Targeting CMV-Associated Cancers
Synopsis
- Explore VBI-1901 targets CMV-antigens that are highly expressed in
glioblastoma - Study a Phase I/II study that has demonstrated improved OS among
vaccine responders - Assess a novel biomarker may predict patients most likely to derive
clinical benefit from VBI-1901
3:15 pm
Afternoon Break & Virtual Networking
3:45 pm SurVaxM, First-of-its-Kind: A Survivin-Targeted Vaccine for Glioblastoma
Synopsis
- Explore how SurVaxM induces strong immune responses involving more
than one arm of the immune system - Assess how strong immune responses to SurVaxM are associated with
longer survival - Discuss OS and PFS, and how they may be extended in patients with
newly diagnosed glioblastoma by treatment with SurVaxM
4:15 pm Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001
Synopsis
- Explore highest exposure cohort yielded significantly higher proinflammatory cytokine serum levels; by 23rd patient, clear that clinical
and radiographic responses were superior in this cohort and protocol amended for ethical reasons to stop randomization. - Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over historical controls.
- Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
4:45 pm A Complete Review of Autologous Dendritic Cells Loaded with Antigens from Self-Renewing Autologous Glioblastoma Cells
Synopsis
- Examine the importance of neoantigens and antigens from tumor initiating cells as an excellent source of antigens for patient-specific vaccines
- Evaluate the advantage of injections of autologous dendritic cells with tumor antigens ex vivo compared to injecting tumor antigens
- A look at enrollment completed for a phase II trial testing for a vaccine, along with chemotherapy and radiation therapy for primary GBM
5:15 pm PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets
Synopsis
- Examine the current treatment options and emerging targeted therapies
- If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients?
- Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?
6:00 pm
Chair’s Closing Remarks
6:15 pm
End of Day One of the 2nd Glioblastoma Drug Development Summit
